New research: Commercial Insight: Antidiabetics - DPP-IV inhibitors poised to sweep the market

Nov. 22, 2009 - PRLog -- Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.

Scope

* Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.
* Event-driven updated sales forecasts for 2009-18 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
* Analysis of major events and brand dynamics affecting the diabetes market.

Highlights

The antidiabetics market in the seven major markets is expected to grow from $20 billion in 2007 to $38 billion in 2018 at a rate of 6.5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.

In 2008, four major insulin therapies dominated the insulin market. This situation is not expected to change throughout the forecast period as there is very limited activity within the insulin antidiabetic pipeline and no serious challenges to the market leading therapies.

The strong market position of Avandia in 2007 has all but been destroyed by a meta-analysis published in mid-2007 and despite GlaxoSmithKline publishing positive data from the RECORD clinical trial in 2009 the drug will not regain market share before its patent expiry.

Reasons to Purchase

* Quantify the future size of the antidiabetics market and identify opportunities for new products.
* Learn how product expiries will shape the antidiabetics market.
* Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.


Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/catalog/product.aspx?productid=4300...

ABOUT DATAMONITOR HEALTHCARE 2
About the Cardiovascular and Metabolic pharmaceutical analysis team 2
CHAPTER 1 EXECUTIVE SUMMARY 3
Datamonitor insight into the disease market 3
Related reports 5
Upcoming related reports 5
CHAPTER 2 MARKET DEFINITION 7
Market definition for this report 7
CHAPTER 3 MARKET OVERVIEW 9
Seven major markets 10
Current market overview 10
Total antidiabetic market 10
Insulin therapies 13
Non-insulin therapies 14
The US dominates the antidiabetic market 16
Historical events 18
Future seven major markets assessment 20
Future events 20
Antidiabetics market assessment 22
Opportunities and threats 42
Opportunities 42
Threats 45
US 52
Current and future market assessment 52
Opportunities and threats 65
Opportunities 65
Threats 66
Japan 80
Current and future market assessment 80
Opportunities and threats 92
Opportunities 92
Threats 94
Five major European markets (5EU) 96
Current and future market assessment 96
Opportunities and threats 110
Opportunities 110
Threats 111
Rest of the world snapshot 113
Current market assessment 113
CHAPTER 4 BRAND DYNAMICS 119
Overview of competitive landscape 119
US formulary tier status for leading brands 121
Actos franchise (pioglitazone; Takeda) 122
Drug profile 122
Franchise overview 123
Product positioning 127
SWOT analysis 132
Brand forecast to 2018 134
Avandia franchise (rosiglitazone; GlaxoSmithKline) 137
Drug profile 137
Franchise overview 137
Product positioning 145
SWOT analysis 148
Brand forecast to 2018 150
Byetta franchise (exenatide; Amylin/Eli Lilly) 153
Drug profile 153
Product positioning 157
SWOT analysis 158
Brand forecast to 2018 160
Januvia franchise (sitagliptin; Merck & Co) 162
Drug profile 162
Franchise overview 163
Product positioning 167
SWOT analysis 169
Brand forecast to 2018 171
Lantus (insulin glargine; Sanofi-Aventis) 173
Drug profile 173
Product positioning 176
SWOT analysis 177
Brand forecast to 2018 178
NovoMix (insulin aspart + insulin aspart protamine; Novo Nordisk) 180
Drug profile 180
Product positioning 181
SWOT analysis 182
Brand forecast to 2018 184
NovoRapid (insulin aspart; Novo Nordisk) 186
Drug profile 186
Product positioning 187
SWOT analysis 187
Brand forecast to 2018 189
CHAPTER 5 KEY DEVELOPERS 191
Strategic overview 191
Trends in corporate strategy 192
Novo Nordisk 195
Specialization in insulin reaps rewards 195
Education targeting physicians. 195
Support services for patients 195
Product development 196
Portfolio assessment 197
Takeda 199
Marketing leading position compromised by missed opportunities 199